Samsung Bioepis announced on the 27th that Vice President Kim Kyung-ah has been promoted and appointed as the new CEO and President.
The new CEO, Kim, holds a bachelor’s and master’s degree in pharmacy from Seoul National University and a Ph.D. in toxicology from Johns Hopkins University. She is an expert in biosimilar (generic drug) development and joined Samsung Electronics’ Advanced Institute of Technology as a senior researcher in biopharmaceutical development in 2010.
She joined Samsung Bioepis in 2015 and has played a key role across the business, including biosimilar development, processing, quality, and regulatory affairs. Samsung Bioepis expressed its expectation that Kim, as the first female professional management CEO within the Samsung Group, will present a growth vision to female talents and create opportunities for bold challenges. They also expect her to become a role model for women, who make up more than half of the workforce, thereby bringing new energy and vitality to the organization.
Samsung Bioepis plans to finalize and announce the regular executive appointments, including those below the vice president level, shortly.